Efforts aiming at overcoming drug resistance in CML, have led to the development of diverse BCR-ABL PROTACs, some of which have shown great activity and selectivity towards various forms of BCR-ABL including mutants that confer resistance to the BCR-ABL inhibitors. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.